drugset / Trial / NCT06307054
CLL-1 CAR-NK Cells for Relapsed/Refractory AML
Phase 1
Recruiting
24 enrolled
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
NaSingle-groupOpen-labelTreatment
Summary
This study is a single-arm, open-label, dose-escalation clinical trial aimed at exploring the safety, tolerability, and pharmacokinetic characteristics of the CLL-1 CAR NK cells, as well as providing preliminary observations on its efficacy in subjects with relapsed/refractory acute myeloid leukemia.
Timeline
- Start
- 2024-04-01
- Primary completion
- 2026-03-15
- Completion
- 2027-03-15
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | anti-CLL-1 CAR NK cells | Cell therapy | 5e+06 cells/kg | — |
| Subject | anti-CLL-1 CAR NK cells | Cell therapy | 1e+07 cells/kg | — |
| Subject | anti-CLL-1 CAR NK cells | Cell therapy | 2e+07 cells/kg | — |
| Subject | anti-CLL-1 CAR NK cells | Cell therapy | 4e+07 cells/kg | — |